Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Another Reason To Believe Mannkind Shares Are Overvalued

|Includes: MannKind Corporation (MNKD)

I already believe Mannkind is overvalued due to it's $2.5 billion market cap, weak balance sheet, and lack of commercial partner. Now they have another possible inhaled insulin competitor with a planned phase 3 trial next year. Take a look at Adam's article for the details.